← Back to Clinical Trials
Recruiting NCT05790785

NCT05790785 Vascular Complications in Children From T1D Diagnosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05790785
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Type 1 Diabetes
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2024-03-25
Primary Completion 2027-09-30

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 18 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2024-03-25 with a primary completion date of 2027-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from T1D diagnosis.

Eligibility Criteria

Inclusion Criteria 1. Between the ages of 8-18 years 2. Within 14 weeks of type 1 diabetes diagnosis 3. Ability and willingness to undergo non-invasive arterial stiffness assessment for 1hr and willingness to wear the 24-h automated blood pressure monitoring (ABPM) device. Exclusion Criteria Children will be ineligible to participate in the study if they meet any of the following: 1. Other cardiometabolic or endocrine diseases diagnosis (type 2 diabetes; familial disorders of cholesterol metabolism; lupus) 2. Other genetic syndromes (Down Syndrome; Prader-Willi) 3. Eating disorder diagnosis 4. Transgender children taking hormone blockers or exogenous sex steroids 5. Currently treated with medications known to affect metabolism (e.g. glucocorticoids, antipsychotics).

Contact & Investigator

Central Contact

Angela Devlin, PhD

✉ adevlin@bcchr.ubc.ca

📞 6048752000

Principal Investigator

Angela Devlin, PhD

PRINCIPAL INVESTIGATOR

UBC Pediatrics/BC Children's Hospital Research Institute

Frequently Asked Questions

Who can join the NCT05790785 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 18 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05790785 currently recruiting?

Yes, NCT05790785 is actively recruiting participants. Contact the research team at adevlin@bcchr.ubc.ca for enrollment information.

Where is the NCT05790785 trial being conducted?

This trial is being conducted at Vancouver, Canada.

Who is sponsoring the NCT05790785 clinical trial?

NCT05790785 is sponsored by University of British Columbia. The principal investigator is Angela Devlin, PhD at UBC Pediatrics/BC Children's Hospital Research Institute. The trial plans to enroll 150 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology